Back to Search Start Over

Efficacy and Tolerability of a New Extended-Release Formulation of Nicotinic Acid in Korean Adults With Mixed Dyslipidemia: An 8-Week, Multicenter, Prospective, Randomized, Double-Blind, and Placebo-Controlled Trial

Authors :
Kim, Sang-Hyun
Kim, Min-Kyung
Lee, Hae-Young
Kang, Hyun-Jae
Kim, Yong-Jin
Park, Byung-Joo
Kim, Hyo-Soo
Source :
Clinical Therapeutics. Oct2011, Vol. 33 Issue 10, p1357-1364. 8p.
Publication Year :
2011

Abstract

Abstract: Background: Nicotinic acid is an effective treatment for dyslipidemia. Patients are more tolerant of the extended-release form of nicotinic acid because it has a lower incidence of side effects, such as facial flushing, than the immediate-release formulation. Objective: This study was designed to evaluate the efficacy and tolerability of an experimental extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia as a regulatory requirement to allow marketing of this product in Korea. Methods: This study was a multicenter, prospective, randomized, double-blind, and placebo-controlled trial. Patients with low high-density lipoprotein cholesterol (HDL-C) levels, high low-density lipoprotein cholesterol (LDL-C) levels, or high triglyceride levels were enrolled. Patients in the treatment group received 500 mg of extended-release niacin for 4 weeks and 1000 mg of extended-release niacin for the next 4 weeks. Results: Twenty-five patients (24% males; mean [SD] age, 57.4 [6.9] years) comprised the treatment group, and 22 patients (5% males; mean [SD] age 61.8 [8.3] years) comprised the placebo group. After 8 weeks of treatment, HDL-C levels were increased significantly in the treatment group (17.6% vs –1.7%, respectively, from 35 [7] mg/dL to 42 [11] mg/dL in the treatment group and from 38 [6] mg/dL to 36 [7] mg/dL in the placebo group; P < 0.001). LDL-C levels were decreased significantly in the treatment group (–11.4% vs 3.6%, respectively, from 147 [33] mg/dL to 126 [22] mg/dL in the treatment group and from 146 [31] mg/dL to 148 [26] mg/dL in the placebo group; P = 0.003). The incidence of drug-related adverse events, including facial flushing in the treatment group, was not significantly different from that in the placebo group. Conclusions: The tested extended-release formulation of nicotinic acid increased HDL-C levels significantly but decreased LDL-C levels with a low incidence of facial flushing in this small, select group of Korean adults with mixed dyslipidemia. [Copyright &y& Elsevier]

Details

Language :
English
ISSN :
01492918
Volume :
33
Issue :
10
Database :
Academic Search Index
Journal :
Clinical Therapeutics
Publication Type :
Academic Journal
Accession number :
66945509
Full Text :
https://doi.org/10.1016/j.clinthera.2011.08.015